In patients with stage II or III CRC who received adjuvant chemotherapy (n = 103), recurrence rates did not differ according to HSP110 T17 deletion size, 23.8% in the large deletion group versus 25.0% in the small deletion group (p = 0.91) or HSP110 expression, 28.0% in the high expression group versus 30.8% in the low expression group (p = 0.50). Here, HSPH1 is linked to colorectal carcinoma.